Understanding and Managing Aggressive Breast Cancer

Date & Location
Sunday, December 4, 2022, 9:00 AM – Monday, December 5, 2022, 5:30 PM, Houston Marriott Medical Center, Houston, TX

Target Audience

Specialties – General Oncology, Pathology/Lab Medicine, Radiation Oncology, Surgical Oncology

AMA PRA Category 1 Credits™ (15.00 hours), Non-Physician Attendance (15.00 hours), General Attendance (13.58 hours), ANCC Contact Hour(s) (13.58 hours)


Inflammatory breast cancer (IBC) is a highly aggressive breast cancer with a very poor prognosis relative to other breast cancers due to its strong potential to metastasize, relapse, and possibly result in patient death. There have been multiple attempts to develop efficacious targeted therapy for this disease. Unfortunately, the federal government (FDA) has not approved any IBC-specific drugs or diagnostic tools yet. Therefore, there remains an urgent need to understand mechanistically how to induce a therapeutic effect that can prolong the survival of patients with IBC. This two-day meeting is targeted for clinical investigators, physicians, basic researchers, nurses, patient advocates and institutions aiming to pioneer IBC clinics in their geographic regions, to enhance their knowledge and to facilitate collaboration to accelerate clinical therapy and research trial development beneficial for patients with IBC. We expect new ideas and collaborations from this meeting to lead to improvement of disease outcome, such as survival or tumor response, over the next 3 years.

ACCME Objectives
  1. Review and acknowledge IBC and non-IBC standard of care diagnosis and treatment
  2. Discuss ongoing clinical trials of IBC and novel new treatments in breast cancer from both the biology perspective and operations to discuss expansion of collaboration in the US
  3. Learn new concepts in the biology and latest developments of the ongoing translational research related to IBC and non-IBC aggressive breast cancer and utilize them in practice
  4. Discuss how we can translate our basic research findings as clinical research or into the clinic
ANCC Learning Outcomes
  1. At the conclusion of this activity, the registered nurse will be able to incorporate the updated standards of practice in the use of immunotherapy and new targeted therapies in the treatment of IBC by self reporting at least 2 new concepts.

On-site registration for the 7th International Inflammatory Breast Cancer Symposium: Understanding and Managing Aggressive Breast Cancer, will open at 9:00 am on Sunday, December 4, 2022, and the symposium will begin at 9:30 am.  The symposium will adjourn at 5:30 pm on Monday, December 5, 2022. Advanced registration is encouraged as space and materials are limited.  Please see registration information for applicable fees.

The deadline for advanced registration is November 9, 2022.


Registration Fees:

Registration Category Before Nov. 9 After Nov. 9 
In-Person Attendance
   Physicians/Scientist (MD, PhD)  $100.00  $125.00
   Healthcare Professionals  $80.00  $95.00
   Trainees  $40.00  $40.00
   Patients, Caregivers, and  Advocates  $20.00  $20.00
Virtual Attendance (Physicians/Scientists, Healthcare Professionals)  $300.00  $350.00
Virtual Attendance (Patients, Advocates, Caregivers)  $50.00  $50.00

Accreditation/Credit Designation – Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Texas MD Anderson Cancer Center and Inflammatory Breast Cancer International Consortium | IBC-IC. The The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 15.00 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center is accredited with distinction as a provider of Nursing Continuing Professional Development by The American Nurses Credentialing Center’s Commission on Accreditation.

The University of Texas MD Anderson Cancer Center designates this live activity will award 13.58 Nursing Continuing Professional Development (NCPD) contact hours.

Translate »

Pin It on Pinterest

Share This